Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial.

ABSTRACT:

Background

Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).

Methods

Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label nintedanib for 40 weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients.

Results

In total, 346 subjects were treated. Mean adherence to weekly home spirometry decre

SUBMITTER: Noth I 

PROVIDER: S-EPMC8264778 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature